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Background: Endothelial dysfunction is an early stage of coronary atherosclerosis and is associated with cardiovascular events. The current study 
was designed to test the hypothesis that long term ET-1 receptor antagonism improves coronary endothelial function in patients with early coronary 
atherosclerosis.
Methods: Seventy-two patients with cardiovascular risk factors, non-obstructive coronary artery disease and coronary endothelial dysfunction were 
randomized in a double blind manner to receive placebo or 10mg of Atrasentan, a specific endothelin A (ETA) receptor antagonist for six months. The 
primary outcomes were the change at six months from baseline of endothelium dependent coronary blood flow (CBF) and coronary artery diameter 
(CAD) measured in response to graded infusion of acetylcholine and endothelium independent coronary flow reserve (CFR) in response to adenosine 
administration.
Results: Baseline characteristics and incidence of adverse effects were similar between the two groups. There was a significant improvement in CBF 
at six months from baseline but not in CAD or CFR (Table 1).
Conclusion: This study demonstrates that long term ET-1 receptor antagonism improves coronary endothelial function in patients with early 
atherosclerosis and suggests that Atrasentan may have a beneficial role in preventing development of atherosclerosis in high cardiovascular risk patients. 
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Difference 39.67 (23.24, 68.22) -2.2 (-27.37, 15.28) 0.0001
% Change CAD (Ach)
Baseline -33.33 (-41.94, -16.30) -21.36 (-45.02, -13.45) 0.07
6 months -34.78 (-48.33,-3.77) -16.67 (-33.39, -6.51) 0.26
P* 0.3 0.84
Difference 1.07 ( -10.40, 20.56) 8.05 ( -17.5, 19.24) 0.6
% Change CFR (Adenosine)
Baseline 2.9 (2.55, 3.2) 3.0 (2.68, 3.82) 0.51
6 months 2.6 (2.2, 2.85) 2.8 (2.4, 3.42) 0.04
P* 0.01 0.06
Difference -0.3 (-1.02, 0) -0.25 (-1.04, 0.1) 0.64
Data presented as median (IQR)
